<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275352</url>
  </required_header>
  <id_info>
    <org_study_id>CLNCKA-1</org_study_id>
    <nct_id>NCT01275352</nct_id>
  </id_info>
  <brief_title>CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression</brief_title>
  <official_title>A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of middle-aged Caucasian non-failing subjects with high blood&#xD;
      pressure who are homozygous for a gene that confers increased risk of developing heart&#xD;
      failure, the Glycine 83 variant of the Ka renal chloride channel (ClC-Ka Gly/Gly 83), or&#xD;
      middle-aged Caucasian non-failing hypertensive subjects who lack the heart failure risk gene,&#xD;
      the wild-type Arginine 83 Ka renal chloride channel (ClC-Ka Arg/Arg 83). Subjects on standard&#xD;
      therapy for high blood pressure with an angiotensin converting inhibitor (ACEI) or&#xD;
      angiotensin receptor blocker (ARB) will be randomized to additional treatment with eplerenone&#xD;
      (an aldosterone antagonist) or placebo, and assessed for changes in echocardiographic left&#xD;
      ventricular hypertrophy (LVMI). Secondary endpoints will assess left ventricular remodeling&#xD;
      and other echocardiographic variables. The investigators hypothesize that subjects homozygous&#xD;
      for the CLCNKA risk allele will have a greater response to eplerenone in terms of reductions&#xD;
      in LVMI than those lacking the risk allele.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The screening phase will involve identifying Caucasian hypertensive patients who are&#xD;
      homozygous for the ClC-Ka Gly/Gly83 and the ClC-Ka Arg/Arg 83 allele. All patients will be on&#xD;
      background therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin&#xD;
      receptor blocker (ARB) at least mid range dosing. If patient is not at recommended dose of&#xD;
      ACE or ARB they must be titrated up and be stable on a midrange dose of ACEI or ARB for at&#xD;
      least 4 weeks before they can be entered into the study. There will be 2 treatment phases.&#xD;
      Phase 1 will be up to 4 weeks in duration and will consist of randomization to one table of&#xD;
      eplerenone (25 mg) or matching placebo. On week 2 the patient will be up titrated to two&#xD;
      tablets of eplerenone (50 mg) or matching placebo, to achieve a target dose of 50 mg of&#xD;
      eplerenone. If the patient cannot tolerate two tablets of eplerenone or matching placebo they&#xD;
      can be down titrated to one tablet of eplerenone or matching placebo. The target BP on study&#xD;
      medication is &lt; 130/80 mmHg. After the patients have been up titrated to the maximally&#xD;
      tolerated dose of study medication, the background hypertension therapy can be adjusted to&#xD;
      reach the target BP of &lt; 130/80 mmHg by the end of week 4. Phase 2 will be 52 weeks in&#xD;
      duration to assess the effects of placebo or eplerenone on LV hypertrophy. Serum potassium&#xD;
      will be monitored throughout the study, and if necessary, doses of eplerenone will be&#xD;
      titrated down as necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LV relative wall thickness</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro-brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV mass index (g/m2)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone 50 mg/day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Inspra</other_name>
    <other_name>aldosterone antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Caucasians with hypertension who are homozygous for the ClC-Ka Gly/Gly83 and the&#xD;
             ClC-Ka Arg/Arg 83 allele.&#xD;
&#xD;
          2. Male or non-pregnant female aged 40 to 80 years.&#xD;
&#xD;
          3. Hypertension, defined as currently taking high blood pressure medications or not on&#xD;
             medications but having SDP &gt;140 or DBP &gt;90.&#xD;
&#xD;
          4. Ejection fraction &gt; 50% by any method within 6 months of the screening visit.&#xD;
&#xD;
          5. The Investigator must obtain written informed consent before the subject is screened&#xD;
             for the study.&#xD;
&#xD;
          6. Subject should be on stable dose of ACE or ARB at moderate dosing for at least 4 weeks&#xD;
             before randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of heart failure with preserved or depressed ejection fraction.&#xD;
&#xD;
          2. Creatinine clearance of &lt; 45 mL/min based on the Cockcroft-Gault formula (Appendix C).&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Life expectancy less than 12 months.&#xD;
&#xD;
          5. Planned cardiac surgery or percutaneous cardiac intervention within 3 months.&#xD;
&#xD;
          6. Serum potassium &gt;5.5 mEq/L.&#xD;
&#xD;
          7. History of hyperkalemia (K&gt;6.0 mEq/L) with eplerenone or spironolactone.&#xD;
&#xD;
          8. Myocardial infarction or stroke within 3 months of screening.&#xD;
&#xD;
          9. Evidence of clinical instability (hypotension, arrhythmias, unstable angina etc.).&#xD;
&#xD;
         10. Subjects on or requiring K-sparing diuretics or spironolactone.&#xD;
&#xD;
         11. Concomitant use of potent inhibitors of CYP3A4 including ketoconazole, itraconazole,&#xD;
             nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir or any drug&#xD;
             noted in the Contraindications, Warnings or Precautions sections of their labeling to&#xD;
             be potent CYP3A4 inhibitors&#xD;
&#xD;
         12. Known hypersensitivity to eplerenone or spironolactone.&#xD;
&#xD;
         13. Evidence of current alcohol or drug abuse Severe organic disorders or surgery or&#xD;
             disease of the gastrointestinal tract that in the opinion of the Investigator may&#xD;
             interfere in the absorption and elimination of the study drug.&#xD;
&#xD;
         14. Psychoses or behavioral conditions that in the opinion of the Investigator would limit&#xD;
             study compliance.&#xD;
&#xD;
         15. Subjects who have received any investigational medication or used any investigational&#xD;
             device within 30 days prior to first dose of study drug or subjects actively&#xD;
             participating in any investigational drug or device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Cappola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Dorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Thomas Cappola, MD, ScM</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

